லாரஸ் ஆய்வகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from லாரஸ் ஆய்வகம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In லாரஸ் ஆய்வகம் Today - Breaking & Trending Today
Laurus Labs’ Q4 net at ₹297 crore April 29, 2021 Its total revenue increased 68% at ₹1,412 crore Laurus Labs Ltd’s consolidated net profit more than doubled at ₹297 crore in the fourth quarter ended March 31, 2021 compared to ₹110 crore in the corresponding quarter of the previous fiscal. The total revenue increased 68 per cent at ₹1,412 crore. For the full year, the net profit increased 286 per cent to ₹984 crore on a revenue of ₹4,814 crore which registered 68 per cent increase over previous financial year. “We delivered a strong performance in all divisions, and we are very confident in strengthening on it further in FY 2022 and beyond. I am extremely happy to share that we have registered a sales increase of ₹1,981 crores in a single financial year,” Satyanarayana Chava – Founder & CEO, Laurus, said in a release issued here on Thursday. ....
Laurus Labs on Thursday said that Satyanarayana Chava, its Founder Promoter, CEO & ED, sold 52 lakh shares of the company. The shares were sold on Thursday at an average price of ₹368.59, ag ....
Explore Now Among largecaps, HCL Technology makes sense valuation wise and there are a lot of opportunities in midcaps also, says Quantum Securities. From a valuation standpoint, how does IT stack up and would you be also looking at a lot of the midcap IT names? Neeraj Dewan: We were looking at midcap IT but after the correction in largecap IT, it makes sense to invest more in IT largecaps. The last quarter’s numbers were pretty good and even the deal wins are good. Stocks like TCS, HCL Tech, Oracle have corrected a little more than 10%. That is a good entry for a lot of investors who had missed the rally earlier. Even now, some of the valuations are not cheap even after the correction. But if you go stock specific, something like HCL Technology would be the better of the lot, valuation wise. We have seen a very good traction in the numbers there and they have a very good deal pipeline going ahead. ....
The pharmaceutical ingredients maker said that its wholly-owned subsidiary, Laurus Synthesis, incorporated a subsidiary by the name of Laurus Ingredients with effect from 9 January 2021.Laurus Ingredients, a step-down subsidiary of Laurus Labs, will undertake ingredients business and will also set up greenfield projects for new synthesis business. The announcement was made after market hours yesterday, 11 January 2021. Laurus Labs consolidated net profit surged 328.4% to Rs 242.27 crore on a 59.9% increase in net sales to Rs 1,138.84 crore in Q2 September 2020 over Q2 September 2019. Shares of Laurus Labs rose 0.50% to Rs 351.90. Laurus Labs is one of the leading manufacturers of API for anti-retroviral (ARV), oncology, cardiovascular, anti-diabetics, anti-asthma, and gastroenterology. ....
Shares of pharmaceutical companies were in focus on Monday with Nifty Pharma index hitting a fresh record high of 12,836 on the National Stock Exchange (NSE) in an otherwise subdued market. Cipla, Cadila Healthcare, Lupin, Sun Pharmaceutical Industries and Aurobindo Pharma from the Nifty Pharma index were up in the range of 1 per cent to 2 per cent on the NSE. Meanwhile, Marksans Pharma, Suven Pharma, Novartis, Indoco Remedies, Glenmark Pharmaceuticals, Dr. Lal PathLabs, RPG Life Sciences, Strides Pharma Science and Laurus Labs from the S&P BSE Healthcare index were up between 2 per cent and 5 per cent. In comparison, the benchmark indices, Nifty50 and S&P BSE Sensex were trading flat at 13,742 points and 46,999 points, respectively, at 10:02 am. ....